GSK Buys Out Neptunus Stake in Chinese Vaccines JV; Are New Pharmacopoeia Standards At Play?
This article was originally published in PharmAsia News
Executive Summary
In an effort to increase its footprint in the Chinese vaccine market, GlaxoSmithKline PLC will acquire the remaining 51% equity stake in its joint venture with China's Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. for $39 million in cash, the companies announced June 14